Mustang Bio Inc logo

MBIO - Mustang Bio Inc Share Price

$3.53 0.1  2.3%

Last Trade - 26/02/21

Small Cap
Market Cap £160.6m
Enterprise Value £106.9m
Revenue £n/a
Position in Universe 4288th / 6718
Unlock MBIO Revenue
Relative Strength (%)
1m -26.6%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -33.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, MustangBio Inc revenues was not reported. Net loss increased 31%to $39.4M. Higher net loss reflects Interest expenseincrease from $1.2M to $3.9M (expense), Research &Development Expense increase of 36% to $1.8M (expense),Interest income decrease of 40% to $567K (income). BasicEarnings per Share excluding Extraordinary Items increasedfrom -$0.89 to -$0.83.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MBIO Revenue Unlock MBIO Revenue

Net Income

MBIO Net Income Unlock MBIO Revenue

Normalised EPS

MBIO Normalised EPS Unlock MBIO Revenue

PE Ratio Range

MBIO PE Ratio Range Unlock MBIO Revenue

Dividend Yield Range

MBIO Dividend Yield Range Unlock MBIO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MBIO EPS Forecasts Unlock MBIO Revenue
Profile Summary

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company’s pipeline is focused in three areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. MB-107 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency. Its MB-102 is a CD123 CAR T cell Program for acute myeloid leukemia (AML).

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated March 13, 2015
Public Since August 22, 2017
No. of Shareholders: 123
No. of Employees: 51
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 65,238,353
Free Float (0.0%)
Eligible for
MBIO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MBIO
Upcoming Events for MBIO
Frequently Asked Questions for Mustang Bio Inc
What is the Mustang Bio Inc share price?

As of 26/02/21, shares in Mustang Bio Inc are trading at $3.53, giving the company a market capitalisation of £160.6m. This share price information is delayed by 15 minutes.

How has the Mustang Bio Inc share price performed this year?

Shares in Mustang Bio Inc are currently trading at $3.53 and the price has moved by 8.15% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Mustang Bio Inc price has moved by -17.93% over the past year.

What are the analyst and broker recommendations for Mustang Bio Inc?

Of the analysts with advisory recommendations for Mustang Bio Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Mustang Bio Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Mustang Bio Inc next release its financial results?

Mustang Bio Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Mustang Bio Inc dividend yield?

Mustang Bio Inc does not currently pay a dividend.

Does Mustang Bio Inc pay a dividend?

Mustang Bio Inc does not currently pay a dividend.

When does Mustang Bio Inc next pay dividends?

Mustang Bio Inc does not currently pay a dividend.

How do I buy Mustang Bio Inc shares?

To buy shares in Mustang Bio Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Mustang Bio Inc?

Shares in Mustang Bio Inc are currently trading at $3.53, giving the company a market capitalisation of £160.6m.

Where are Mustang Bio Inc shares listed? Where are Mustang Bio Inc shares listed?

Here are the trading details for Mustang Bio Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: MBIO
What kind of share is Mustang Bio Inc?

Based on an overall assessment of its quality, value and momentum, Mustang Bio Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Mustang Bio Inc share price forecast 2021?

Shares in Mustang Bio Inc are currently priced at $3.53. At that level they are trading at 0.212% discount to the analyst consensus target price of 0.00.

Analysts covering Mustang Bio Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.012 for the next financial year.

How can I tell whether the Mustang Bio Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mustang Bio Inc. Over the past six months, the relative strength of its shares against the market has been -5.05%. At the current price of $3.53, shares in Mustang Bio Inc are trading at -0.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Mustang Bio Inc PE Ratio?

We were not able to find PE ratio data for Mustang Bio Inc.

Who are the key directors of Mustang Bio Inc?

Mustang Bio Inc's management team is headed by:

Manuel Litchman - PRE
Brian Achenbach - SVF
Michael Weiss - CHM
Lindsay Rosenwald - DRC
Neil Herskowitz - IND
Adam Chill - IND
Michael Zelefsky - IND
Who are the major shareholders of Mustang Bio Inc?

Here are the top five shareholders of Mustang Bio Inc based on the size of their shareholding:

Fortress Biotech Inc Corporation
Percentage owned: 19.99% (12.9m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.84% (3.13m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.34% (2.16m shares)
Millennium Management LLC Hedge Fund
Percentage owned: 2.94% (1.90m shares)
iShares Russell 2000 ETF Mutual Fund
Percentage owned: 1.93% (1.25m shares)
Similar to MBIO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.